Target intelligence / Profile preview

Zaire ebolavirus glycoprotein internal fusion loop (EBOV GP IFL) (EBOV GP IFL)

Target
EBOV GP IFL
Molecular classification
Viral envelope protein, Class I viral fusion protein subunit
01

Overview

The Zaire ebolavirus glycoprotein internal fusion loop (IFL) is a highly conserved, hydrophobic region located within the GP2 subunit of the Ebola virus (EBOV) spike protein (UniProt: P87666). It plays a pivotal role in the viral entry process by mediating the fusion between the viral envelope and the host cell endosomal membrane (PubMed: 27184314). Following macropinocytosis and proteolytic priming of the GP1 subunit by host cathepsins to expose the receptor-binding domain for Niemann-Pick C1 (NPC1), the IFL is projected toward and inserts into the host membrane. Because of its essential role in membrane fusion and its high degree of sequence conservation among filoviruses, the IFL is a primary target for the development of neutralizing monoclonal antibodies and fusion-inhibiting small molecules (PubMed: 29109255). Therapeutic agents targeting this site, such as the antibodies ADI-15878 and CA45, typically function by preventing the structural rearrangement of GP2 into its post-fusion six-helix bundle state. This action effectively traps the virus within the endosome and prevents the infection of the host cell (PubMed: 28100724). The high conservation of this loop suggests that therapies targeting it may provide broad protection against multiple ebolavirus species.

Other names
Ebola virus GP2 fusion loopGP2 internal fusion loopEBOV GP-IFLEbolavirus fusion peptideGP2-IFL
02

Mechanism of action

Neutralization of viral infectivity by binding to the GP2 internal fusion loop, thereby preventing its insertion into the host endosomal membrane and inhibiting the conformational change required for membrane fusion (PubMed: 28100724).

03

Biological functions

Viral-host membrane fusionViral entryEndosomal escape
04

Disease associations

Ebola virus diseaseViral infection
05

Safety considerations

Viral escape through antigenic drift in the GP2 subunitTheoretical risk of antibody-dependent enhancement (ADE)Requirement for therapeutic agents to reach the endosomal compartment for efficacy (PubMed: 29109255)
06

Interacting drugs

ADI-15878

4 more in the full profile.

07

Biomarkers

EBOV RNA viral loadGP-specific antibody titersSoluble glycoprotein (sGP) levels

Beyond the preview

Go deeper on Zaire ebolavirus glycoprotein internal fusion loop (EBOV GP IFL) (EBOV GP IFL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zaire ebolavirus glycoprotein internal fusion loop (EBOV GP IFL) (EBOV GP IFL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call